TG THERAPEUTICS, INC. (TGTX) Form 10-Q — Aug 5, 2026
TG Therapeutics reported Q2 2026 total revenue of $240.3 million, up roughly 70% from $141.1 million a year earlier, driven by U.S. BRIUMVI net sales of $227.7 million plus $8.1 million of product supplied to ex-U.S. partner Neuraxpharm. Despite the top-line surge, Q2 net income fell to $7.8 million ($0.05 diluted EPS) from $28.2 million ($0.17 diluted) as R&D nearly tripled to $95.3 million on subcutaneous ublituximab work and interest expense more than doubled to $16.6 million following the March 2026 refinancing into a $750 million Blue Owl Capital term loan maturing March 2031.
Key figures
- Eps
- 0.05
- Revenue
- 240335000
- Net Income
- 7781000
- Total Debt
- 745387000
- Debt Amount
- 750000000
- Revenue Yoy
- 70% (Q2 2026 vs Q2 2025)
- Total Assets
- 1639629000
- Cash Position
- 482575000
- Interest Rate
- Applicable margin (starting 4.75% for SOFR borrowings) plus base rate/SOFR under 2026 Term Loan pricing grid
- Maturity Date
- March 18, 2031
- Shares Outstanding
- 153069053
- Q2 Rn DExpense
- 95337000
- Six Month Revenue
- 445253000
- Q2 Interest Expense
- 16572000
- Q2 Operating Income
- 21674000
- Six Month Net Income
- 27558000
- Accumulated Deficit
- 1054457000
- Buyback Program Size
- $300 million (expanded from $100 million in March 2026)
- Cash Plus Investments
- 612300000
- Q2 Us Briumvi Net Sales
- 227700000
- Gross Margin Us Briumvi
- approximately 87%
- Six Month Operating Cash Flow
- 21369000
- Buyback Repurchased2025 Program
- $100.0 million at average $30.44 per share
- Precision Equity Investment Fair Value
- 4084000
- Deferred Revenue Neuraxpharm Optional Purchases
- 31400000
Price after filing
Close on the filing date to close N calendar days later (from $49.88). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.